The Integration of Artificial Intelligence in Pharmacovigilance. Transforming Drug Safety
About this episode
This episode discusses how AI is transforming pharmacovigilance and drug safety in the pharmaceutical industry.
Artificial Intelligence is Reshaping Pharmacovigilance – But Are You Ready? With over 1.5 million adverse drug reactions reported annually in the EU alone, the pressure on pharmacovigilance systems has never been greater. Could artificial intelligence (AI) be the answer? In this episode of International Pharma Talks , Dr. Diogo Sousa-Martins, Founder and President of ELS Group, discusses how AI is transforming the landscape of drug safety, and what pharmaceutical companies must do to stay ahead. From automation and real-time signal detection to regulatory hurdles and ethical challenges, we break down how AI is redefining the future of pharmacovigilance and what that means for compliance, patient safety, and innovation. You’ll learn more about: How AI enhances adverse event detection across large, unstructured data sources Compliance requirements under EMA, FDA, and ISO standards Why early-stage integration of AI is a strategic (not optional) investment How companies can adopt scalable, cost-effective AI solutions without compromising compliance The integration of AI into pharmacovigilance isn’t a distant possibility, it’s an urgent priority. But real transformation requires more…
More episodes of International Pharma Talks
- Global Operations Management and practical strategies for integrating international markets
- The Path to Successful Distribution of Medical Devices
- Impacto na Falsificação de Bebidas e Alimentos: Como Proteger Consumidores e Marcas
- How Efficiency in Import and Distribution Logistics Drives Global Success
- Exploring the market and regulatory opportunities of medicinal cannabis in Brazil
- Changes and Evolution in the Pharmaceutical Market
Explore listener stats, chart rankings, contacts and more on the International Pharma Talks podcast page.